These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 18324783)

  • 1. Why clinically used tazobactam and sulbactam are poor inhibitors of OXA-10 beta-lactamase: Raman crystallographic evidence.
    Totir MA; Cha J; Ishiwata A; Wang B; Sheri A; Anderson VE; Buynak J; Mobashery S; Carey PR
    Biochemistry; 2008 Apr; 47(13):4094-101. PubMed ID: 18324783
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallography.
    Helfand MS; Totir MA; Carey MP; Hujer AM; Bonomo RA; Carey PR
    Biochemistry; 2003 Nov; 42(46):13386-92. PubMed ID: 14621983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamase.
    Totir MA; Helfand MS; Carey MP; Sheri A; Buynak JD; Bonomo RA; Carey PR
    Biochemistry; 2007 Aug; 46(31):8980-7. PubMed ID: 17630699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different intermediate populations formed by tazobactam, sulbactam, and clavulanate reacting with SHV-1 beta-lactamases: Raman crystallographic evidence.
    Kalp M; Totir MA; Buynak JD; Carey PR
    J Am Chem Soc; 2009 Feb; 131(6):2338-47. PubMed ID: 19161282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tazobactam forms a stoichiometric trans-enamine intermediate in the E166A variant of SHV-1 beta-lactamase: 1.63 A crystal structure.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Hujer AM; Carey PR; Bonomo RA; van den Akker F
    Biochemistry; 2004 Feb; 43(4):843-8. PubMed ID: 14744126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of bacterial strains producing sulbactam- or tazobactam-sensitive beta-lactamases by the use of disks containing the inhibitors alone instead of combining them with antibiotics.
    Banic S
    APMIS; 2006 Jan; 114(1):3-9. PubMed ID: 16499654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamase.
    Padayatti PS; Helfand MS; Totir MA; Carey MP; Carey PR; Bonomo RA; van den Akker F
    J Biol Chem; 2005 Oct; 280(41):34900-7. PubMed ID: 16055923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the inhibition of CTX-M-9 by beta-lactamase inhibitors and carbapenems.
    Bethel CR; Taracila M; Shyr T; Thomson JM; Distler AM; Hujer KM; Hujer AM; Endimiani A; Papp-Wallace K; Bonnet R; Bonomo RA
    Antimicrob Agents Chemother; 2011 Jul; 55(7):3465-75. PubMed ID: 21555770
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediates.
    Totir MA; Padayatti PS; Helfand MS; Carey MP; Bonomo RA; Carey PR; van den Akker F
    Biochemistry; 2006 Oct; 45(39):11895-904. PubMed ID: 17002290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
    Sun T; Bethel CR; Bonomo RA; Knox JR
    Biochemistry; 2004 Nov; 43(44):14111-7. PubMed ID: 15518561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
    Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
    Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming resistance to beta-lactamase inhibitors: comparing sulbactam to novel inhibitors against clavulanate resistant SHV enzymes with substitutions at Ambler position 244.
    Thomson JM; Distler AM; Bonomo RA
    Biochemistry; 2007 Oct; 46(40):11361-8. PubMed ID: 17848099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Theoretical investigation on reaction of sulbactam with wild-type SHV-1 β-lactamase: acylation, tautomerization, and deacylation.
    Li R; Liao JM; Gu CR; Wang YT; Chen CL
    J Phys Chem B; 2011 Sep; 115(34):10298-310. PubMed ID: 21797222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative activities of the beta-lactamase inhibitors YTR 830, clavulanic acid and sulbactam combined with ampicillin and piperacillin against beta-lactamase producing anaerobic bacteria.
    Nord CE
    J Chemother; 1989 Jul; 1(4 Suppl):273-5. PubMed ID: 16312398
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of class D beta-lactamases by diaroyl phosphates.
    Majumdar S; Adediran SA; Nukaga M; Pratt RF
    Biochemistry; 2005 Dec; 44(49):16121-9. PubMed ID: 16331972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of OXA-1 beta-lactamase by penems.
    Bethel CR; Distler AM; Ruszczycky MW; Carey MP; Carey PR; Hujer AM; Taracila M; Helfand MS; Thomson JM; Kalp M; Anderson VE; Leonard DA; Hujer KM; Abe T; Venkatesan AM; Mansour TS; Bonomo RA
    Antimicrob Agents Chemother; 2008 Sep; 52(9):3135-43. PubMed ID: 18559643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toward better antibiotics: crystallographic studies of a novel class of DD-peptidase/beta-lactamase inhibitors.
    Silvaggi NR; Kaur K; Adediran SA; Pratt RF; Kelly JA
    Biochemistry; 2004 Jun; 43(22):7046-53. PubMed ID: 15170342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detecting a quasi-stable imine species on the reaction pathway of SHV-1 β-lactamase and 6β-(hydroxymethyl)penicillanic acid sulfone.
    Che T; Rodkey EA; Bethel CR; Shanmugam S; Ding Z; Pusztai-Carey M; Nottingham M; Chai W; Buynak JD; Bonomo RA; van den Akker F; Carey PR
    Biochemistry; 2015 Jan; 54(3):734-43. PubMed ID: 25536850
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A kinetic study on the interaction between tazobactam (a penicillanic acid sulphone derivative) and active-site serine beta-lactamases.
    Perilli M; Franceschini N; Bonfiglio G; Segatore B; Stefani S; Nicoletti G; Perez MM; Bianchi C; Zollo A; Amicosante G
    J Enzyme Inhib; 2000; 15(1):1-10. PubMed ID: 10850951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic properties of beta-lactamase inhibitors.
    de la Pena A; Derendorf H
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):63-75. PubMed ID: 10082170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.